CN115501245A - 抗产道细胞损伤促弹性蛋白合成的组分及应用 - Google Patents
抗产道细胞损伤促弹性蛋白合成的组分及应用 Download PDFInfo
- Publication number
- CN115501245A CN115501245A CN202211250066.7A CN202211250066A CN115501245A CN 115501245 A CN115501245 A CN 115501245A CN 202211250066 A CN202211250066 A CN 202211250066A CN 115501245 A CN115501245 A CN 115501245A
- Authority
- CN
- China
- Prior art keywords
- composition
- smooth muscle
- cordycepin
- nmn
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 37
- 102000016942 Elastin Human genes 0.000 title claims abstract description 35
- 108010014258 Elastin Proteins 0.000 title claims abstract description 35
- 229920002549 elastin Polymers 0.000 title claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 19
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 18
- 230000005779 cell damage Effects 0.000 title abstract description 9
- 208000037887 cell injury Diseases 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 146
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 109
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims abstract description 97
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 97
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims abstract description 97
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract description 59
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 17
- 210000004994 reproductive system Anatomy 0.000 claims abstract description 17
- 230000004083 survival effect Effects 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000008367 deionised water Substances 0.000 claims abstract description 11
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 30
- 210000002460 smooth muscle Anatomy 0.000 claims description 30
- 210000004907 gland Anatomy 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 229920002674 hyaluronan Polymers 0.000 claims description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 239000012456 homogeneous solution Substances 0.000 claims description 6
- 230000035899 viability Effects 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 108010045569 atelocollagen Proteins 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000008828 contractile function Effects 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 210000004325 uterine smooth muscle cell Anatomy 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 abstract description 16
- 241001465754 Metazoa Species 0.000 abstract description 15
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 210000001215 vagina Anatomy 0.000 abstract description 8
- 230000000762 glandular Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 230000026799 smooth muscle cell apoptotic process Effects 0.000 abstract 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 102000002045 Endothelin Human genes 0.000 description 8
- 108050009340 Endothelin Proteins 0.000 description 8
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000029549 Muscle injury Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 206010051873 Vaginal relaxation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010046763 Uterine atony Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007128 effect on nervous system disease Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008802 morphological function Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211250066.7A CN115501245B (zh) | 2022-10-12 | 2022-10-12 | 抗产道细胞损伤促弹性蛋白合成的组分及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211250066.7A CN115501245B (zh) | 2022-10-12 | 2022-10-12 | 抗产道细胞损伤促弹性蛋白合成的组分及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115501245A true CN115501245A (zh) | 2022-12-23 |
CN115501245B CN115501245B (zh) | 2023-10-31 |
Family
ID=84509983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211250066.7A Active CN115501245B (zh) | 2022-10-12 | 2022-10-12 | 抗产道细胞损伤促弹性蛋白合成的组分及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115501245B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893200A (zh) * | 2012-12-26 | 2014-07-02 | 中国医学科学院药用植物研究所 | 虫草素用于制备预防和治疗动脉粥样硬化的药物 |
US20150209380A1 (en) * | 2012-08-23 | 2015-07-30 | Beijing Gragen Biotechnology Co. Ltd. | Use of cordycepin in manufacture of medicaments for anti-depression |
CN109463730A (zh) * | 2018-12-27 | 2019-03-15 | 深圳松乐生物科技有限公司 | 一种含有虫草素的组合物、液体饮料、糖果、固体饮料和片剂 |
CN111973614A (zh) * | 2020-07-28 | 2020-11-24 | 南华大学 | 烟酰胺单核苷酸在制备预防、改善和/或治疗囊卵巢综合症的药物中的应用 |
WO2020244249A1 (zh) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技(深圳)有限公司 | 含烟酰胺单核苷酸的组合物在抗衰老药品/保健品的应用 |
-
2022
- 2022-10-12 CN CN202211250066.7A patent/CN115501245B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150209380A1 (en) * | 2012-08-23 | 2015-07-30 | Beijing Gragen Biotechnology Co. Ltd. | Use of cordycepin in manufacture of medicaments for anti-depression |
CN103893200A (zh) * | 2012-12-26 | 2014-07-02 | 中国医学科学院药用植物研究所 | 虫草素用于制备预防和治疗动脉粥样硬化的药物 |
CN109463730A (zh) * | 2018-12-27 | 2019-03-15 | 深圳松乐生物科技有限公司 | 一种含有虫草素的组合物、液体饮料、糖果、固体饮料和片剂 |
WO2020244249A1 (zh) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技(深圳)有限公司 | 含烟酰胺单核苷酸的组合物在抗衰老药品/保健品的应用 |
CN111973614A (zh) * | 2020-07-28 | 2020-11-24 | 南华大学 | 烟酰胺单核苷酸在制备预防、改善和/或治疗囊卵巢综合症的药物中的应用 |
Non-Patent Citations (1)
Title |
---|
HUANG, GUOTAO ET AL.: "Restoration of NAD+ homeostasis protects C2C12 myoblasts and mouse levator ani muscle from mechanical stress-induced damage", ANIMAL CELLS AND SYSTEMS, vol. 26, no. 4, pages 192 - 202 * |
Also Published As
Publication number | Publication date |
---|---|
CN115501245B (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smith et al. | Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts | |
Ellenbogen et al. | An improved urinary excretion test as an assay for intrinsic factor. | |
CN110051677A (zh) | 一种栀子苷在缓解糖皮质激素副作用方面的应用 | |
CN107375910A (zh) | PTHrP在制备治疗男性性腺功能低下综合征中的应用 | |
US7311919B2 (en) | Agents for treating osteoporosis and inhibiting osteoclast formation | |
CN102824400A (zh) | 包含杜仲和续断的组合物及其治疗骨质疏松症的用途 | |
CN115501245A (zh) | 抗产道细胞损伤促弹性蛋白合成的组分及应用 | |
EP3738581A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
CN117122527A (zh) | 一种护肤组合物、含护肤组合物的抗衰化妆品及其应用 | |
Toda et al. | Ultrastructural changes in the comb and aorta of chicks fed excess testosterone | |
CN111110581A (zh) | 具有提高美白功能的新琼寡糖组合物及其应用 | |
CN106420771A (zh) | 二氢丹参酮i和原儿茶醛联合用于制备治疗急性心肌梗死药物的应用 | |
CN114099366B (zh) | 一种促进细胞能量代谢的无菌抗衰祛皱组合液及其制备方法和应用 | |
Walker et al. | Effects of glucocorticoids on the growth of human fibrosarcoma cell line HT-1080 | |
CN106806403B (zh) | 一种增加骨密度的中药复方组合物及其制备方法 | |
CN115154356B (zh) | 一组胶原蛋白组合在制备抗衰老产品中的应用以及包括其的外用化妆品 | |
CN106924274B (zh) | 葫芦烷型四环三萜类化合物抗肺纤维化应用 | |
CN115998741A (zh) | 一种抗肿瘤药物组合物及其制备方法和应用 | |
CN115804813B (zh) | 一种发酵虫草菌粉微球复合液及其制备方法和应用 | |
RU2760674C1 (ru) | Применение препаратов растения polyscias filicifolia или его фрагментов для лечения элементозов и их последствий | |
CN117942276B (zh) | 一种实现低浓度下经皮吸收促进成纤维细胞增殖的复配肽及制法 | |
CN115919850B (zh) | 一种抗阿霉素心脏毒性的中药单体组合物及其制备方法和应用 | |
CN116370485B (zh) | 2-羟基苯基α-D-吡喃葡萄糖苷在制备治疗骨质疏松症药物中的应用 | |
CN113244405B (zh) | 佛司可林/异佛司可林与五环三萜类化合物的药物组合物及其应用 | |
US20220339214A1 (en) | Kirin fruit fermentation and methods for improving metabolism by using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230324 Address after: 710046 Room 10101, Unit 1, Building 1, Science and Technology Enterprise Accelerator Zone 2, No. 6 West Qinling Avenue, Caotang Science and Technology Industry Base, Gaoxin District, Xi'an City, Shaanxi Province Applicant after: Xi'an Xuanyu Pharmaceutical Group Co.,Ltd. Address before: 100081 Minzu University of China, 27 Zhongguancun South Street, Haidian District, Minzu University of China Applicant before: Liu Di |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240312 Address after: 215100 Suzhou City, Jiangsu Province, China (Jiangsu) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Suzhou Central Plaza Building 6 Suzhou Central Office Building C 22nd Floor 03 Patentee after: Hehaopin (Suzhou) Technology Co.,Ltd. Country or region after: China Address before: 710046 Room 10101, Unit 1, Building 1, Science and Technology Enterprise Accelerator Zone 2, No. 6 West Qinling Avenue, Caotang Science and Technology Industry Base, Gaoxin District, Xi'an City, Shaanxi Province Patentee before: Xi'an Xuanyu Pharmaceutical Group Co.,Ltd. Country or region before: China |